ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
Rhea-AI Summary
ANI Pharmaceuticals (NASDAQ: ANIP) has scheduled its second quarter 2025 financial results announcement for Friday, August 8, 2025, before market open. The company will host a conference call at 8:30 a.m. ET to discuss the results.
Key executives participating in the call include CEO Nikhil Lalwani, CFO Stephen P. Carey, Head of Rare Disease Chris Mutz, and Chief Medical Officer Mary Pao, M.D., Ph.D. Investors can access the call via toll-free number 800-343-4136 using conference ID 5034065. A webcast will be available on the company's website under the Investors section.
Positive
- None.
Negative
- None.
News Market Reaction – ANIP
On the day this news was published, ANIP gained 0.92%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open.
Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, Chris Mutz, Head of Rare Disease, and Mary Pao, M.D., Ph.D., Chief Medical Officer, will host a conference call to discuss the results as follows:
| Date | Friday, August 8, 2025 |
| Time | 8:30 a.m. ET |
| Toll free (U.S.) | 800-343-4136 |
| Conference ID | 5034065 |
| Webcast (live and replay) | www.anipharmaceuticals.com, under the “Investors” section |
A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-839-6803 and entering access code 5034065.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.
Investor Relations Contact:
Lisa M. Wilson, In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com
SOURCE: ANI Pharmaceuticals, Inc.
FAQ
When will ANI Pharmaceuticals (ANIP) release Q2 2025 earnings?
How can investors access ANI Pharmaceuticals' Q2 2025 earnings call?
Who will be presenting at ANI Pharmaceuticals' Q2 2025 earnings call?
How long will ANI Pharmaceuticals' Q2 2025 earnings call replay be available?
